Regentis Biomaterials (NYSE American: RGNT) announced it has received approval from the European Notified Body to manufacture GelrinC(R) using its next-generation solvent-free manufacturing process, a milestone that supports the product’s planned commercial launch in Europe. The company said the new process increases production yield by approximately 400%, producing five times more product from the same manufacturing volume while improving manufacturing efficiency, scalability and occupational and environmental safety. Extensive clinical testing validated consistent product quality and clinical performance.
GelrinC(R), which has already received CE Mark approval in Europe, is a proprietary, cell-free hydrogel implant designed to regenerate cartilage through a minimally invasive 10-minute procedure. Regentis said commercialization will be supported through its expanding European Centers of Excellence, surgeon training programs and collaborations with leading orthopedic institutions, including Humanitas Research Hospital in Milan, targeting a U.S. cartilage repair market valued at approximately $3 billion.
To view the full press release, visit https://ibn.fm/Ths4h. The latest news and updates relating to RGNT are available in the company’s newsroom at https://ibn.fm/RGNT.
This approval is significant because it addresses a key barrier to commercial scale-up: manufacturing efficiency. The 400% yield increase means Regentis can supply the European market more cost-effectively, potentially making GelrinC more accessible to patients. The solvent-free process also reduces environmental and occupational hazards, aligning with broader sustainability trends in medical device manufacturing. For investors, this milestone de-risks the company’s path to revenue generation in Europe and strengthens its position in the $3 billion U.S. cartilage repair market, where no off-the-shelf treatment is currently available for the estimated 470,000 annual knee repair cases. The collaboration with institutions like Humanitas Research Hospital adds clinical credibility and could accelerate adoption among surgeons.
Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. With an initial focus on orthopedic treatments, Regentis’ Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. Regentis’ lead product GelrinC(R), is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing the surrounding cells to regenerate the cartilage in a controlled and synchronous process. GelrinC(R) aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available.
Forward-looking statements in this article involve risks and uncertainties, including those described in the company's SEC filings. See http://IBN.fm/Disclaimer for full terms.
